Clarity Trial

adni logo

Get Involved with the Study

If you would like to find out more, you can call toll free at 1-844-563-6679, or email memory@lifespan.org.

Anti-Amyloid Antibody Treatment Study for Individuals with Early Alzheimer’s Disease

Researchers at Rhode Island Hospital at the Alzheimer’s Disease and Memory Disorders Center (ADMDC) are recruiting for a new phase III clinical trial of an anti-amyloid antibody, BAN2401, for patients with early Alzheimer’s disease. BAN2401 works by selectively targeting toxic forms of amyloid-beta in the brain.  

This investigational medication is being jointly developed by Eisai and Biogen, leading companies in the field. The purpose of this study is to determine the safety and efficacy of BAN2401 in treating people with Mild Cognitive Impairment or mild Alzheimer’s disease. Only individuals with elevated levels of amyloid plaques on a brain PET scan are eligible. In this placebo-controlled study, BAN2401 will be given intravenously twice a month for 18 months. After completing the initial 18-month period, all participants may be offered the opportunity to receive the study drug and continue in the trial. 

Eligible Participants

This study is seeking individuals ages 50-90 years old who have a diagnosis of Mild Cognitive Impairment or mild Alzheimer’s disease.  All participants must have a study partner who is able to come to some of the study visits.  

If you are interested in volunteering for the BAN2401 study or have questions about our research, contact the Rhode Island Hospital ADMDC at 1-844-5MEMORY (1-844-563-6679) or email memory@lifespan.org.